‘Ecstasy’ Use Studied to Ease Fear in Terminally Ill

The Washington Post Monday, December 27, 2004 http://www.washingtonpost.com/wp-dyn/articles/A27716-2004Dec26.html "Ecstasy" Use Studied to Ease Fear in Terminally Ill by Rick Weiss For some, the diagnosis …

event_id1622

MAPS Benefit Dinner and Dance at Alex’s Grey’s Chapel of Sacred Mirriors We are thrilled to announce this special event held at Alex Grey‘s new sacred art space. The evening event will …

Article: Wired: Long Trip for Psychedelic Drugs

Wired published a piece charting the progress of research into the therapeutic uses of psychedelic drugs, including the ongoing studies of MDMA-assisted psychotherapy in people with PTSD, psilocybin in …

Article: BBC News: Medicine Hope for Psychedelic Drugs

Medicine Hope for Psychedelic Drugs, an article from BBC News (UK Web), by Arran Frood, discussed psychedelic psychotherapy research supported by Heffter Research Institute and MAPS. This article is mostly …

FY 2004 Financial Report

The basic balance sheet information for FY 2003-2004 is presented below. MAPS IRS Form 990 for 2004 is available in PDF format.MAPS total income for FY 2003-2004 was $1,035,873. A chart presenting comparative …

16th International Transpersonal Conference

June 12-18, 2004. Dr. Stan Grof and the International Transpersonal Association (ITA) organized the “16th International Transpersonal Conference,” at Palm Springs, California. MAPS sponsored …

Timeline of Vaporizer Research News 2004 and prior

Congressman Mark Souder, Chairman of the U.S. House Government Reform Subcommittee on Criminal Justice, Drug Policy, and Human Resources, held a hearing about “Marijuana and Medicine: The Need for …

Psilocybin: Basic Dose-Response Safety Studies

Investigator: Franz Vollenweider, MD Psychiatric University Hospital Zurich, Switzerland Contact: Sponsor: Heffter Dr. Vollenweider’s team have completed a series of basic research studies into the …

Psilocybin: Basic Dose-Response Safety Studies

Investigator: Franz Vollenweider, MD Psychiatric University Hospital Zurich, Switzerland Contact: Sponsor: Heffter Dr. Vollenweider’s team have completed a series of basic research studies into the …